HUE046194T2 - 18F-jelölt PSMA-célzott PET képalkotó ágensek - Google Patents

18F-jelölt PSMA-célzott PET képalkotó ágensek

Info

Publication number
HUE046194T2
HUE046194T2 HUE14721640A HUE14721640A HUE046194T2 HU E046194 T2 HUE046194 T2 HU E046194T2 HU E14721640 A HUE14721640 A HU E14721640A HU E14721640 A HUE14721640 A HU E14721640A HU E046194 T2 HUE046194 T2 HU E046194T2
Authority
HU
Hungary
Prior art keywords
imaging agents
pet imaging
labeled psma
targeted pet
targeted
Prior art date
Application number
HUE14721640A
Other languages
English (en)
Inventor
Clifford Berkman
Svetlana Stekhova
Original Assignee
Cancer Targeted Tech Llc
Univ Washington State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Tech Llc, Univ Washington State filed Critical Cancer Targeted Tech Llc
Publication of HUE046194T2 publication Critical patent/HUE046194T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0489Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2416Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE14721640A 2013-03-15 2014-03-14 18F-jelölt PSMA-célzott PET képalkotó ágensek HUE046194T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361798108P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE046194T2 true HUE046194T2 (hu) 2020-02-28

Family

ID=50639969

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE19179758A HUE061402T2 (hu) 2013-03-15 2014-03-14 18F-jelölt PSMA-célzott PET képalkotó ágensek elõállításának módszerei és diagnosztikai módszerek velük
HUE14721640A HUE046194T2 (hu) 2013-03-15 2014-03-14 18F-jelölt PSMA-célzott PET képalkotó ágensek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE19179758A HUE061402T2 (hu) 2013-03-15 2014-03-14 18F-jelölt PSMA-célzott PET képalkotó ágensek elõállításának módszerei és diagnosztikai módszerek velük

Country Status (16)

Country Link
US (2) US11554183B2 (hu)
EP (3) EP2970345B1 (hu)
CN (2) CN108558939B (hu)
AU (2) AU2014228233B2 (hu)
CA (1) CA2903131C (hu)
DK (2) DK3560937T3 (hu)
ES (2) ES2937955T3 (hu)
FI (1) FI3560937T3 (hu)
HR (2) HRP20230109T1 (hu)
HU (2) HUE061402T2 (hu)
LT (2) LT2970345T (hu)
PL (2) PL2970345T3 (hu)
PT (2) PT3560937T (hu)
RS (1) RS64011B1 (hu)
SI (2) SI3560937T1 (hu)
WO (1) WO2014143736A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078166B2 (en) 2015-08-13 2021-08-03 The Johns Hopkins University Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof
EP3497108A1 (en) * 2016-08-10 2019-06-19 Cancer Targeted Technology LLC Chelated psma inhibitors
US11963775B2 (en) 2017-03-22 2024-04-23 Safeop Surgical, Inc. Medical systems and methods for detecting changes in electrophysiological evoked potentials
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG NOVEL PSMA BINDING AGENTS AND USE THEREOF
US11629201B2 (en) 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020224780A1 (en) 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
IL307381A (en) 2021-04-02 2023-11-01 Advanced Accelerator Applications Diagnostic methods of prostate cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696185B2 (en) * 2006-03-14 2010-04-13 Cancer Targered Technology LLC Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
US8557776B2 (en) * 2006-09-08 2013-10-15 Bayer Pharma AG Compounds and methods for 18F labeled agents
CN107382846B (zh) * 2008-08-01 2021-07-06 约翰.霍普金斯大学 Psma-结合剂及其用途
WO2012064914A2 (en) * 2010-11-12 2012-05-18 Washington State University Research Foundation Peptidomimetic inhibitors of psma
EP2721039B1 (en) * 2011-06-15 2018-01-10 Cancer Targeted Technology LLC Chelated psma inhibitors
CN102757296B (zh) * 2012-04-10 2014-11-19 中国科学院上海应用物理研究所 一种对化合物进行[18f]标记的方法
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors

Also Published As

Publication number Publication date
ES2743433T3 (es) 2020-02-19
CN108558939A (zh) 2018-09-21
EP2970345A1 (en) 2016-01-20
CN108558939B (zh) 2021-08-24
AU2014228233A1 (en) 2015-09-17
CA2903131A1 (en) 2014-09-18
AU2019203610A1 (en) 2019-06-13
SI2970345T1 (sl) 2019-11-29
HUE061402T2 (hu) 2023-06-28
PL2970345T3 (pl) 2019-12-31
US20160030605A1 (en) 2016-02-04
HRP20191482T1 (hr) 2019-11-15
PT3560937T (pt) 2023-02-13
CA2903131C (en) 2021-11-23
US11554183B2 (en) 2023-01-17
EP3560937A1 (en) 2019-10-30
EP3560937B1 (en) 2022-12-28
FI3560937T3 (fi) 2023-02-28
AU2014228233B2 (en) 2019-02-28
PT2970345T (pt) 2019-09-06
PL3560937T3 (pl) 2023-03-27
US20230144322A1 (en) 2023-05-11
CN105308056A (zh) 2016-02-03
CN105308056B (zh) 2018-03-20
LT3560937T (lt) 2023-03-27
WO2014143736A1 (en) 2014-09-18
HRP20230109T1 (hr) 2023-04-28
DK2970345T3 (da) 2019-08-26
LT2970345T (lt) 2019-09-25
ES2937955T3 (es) 2023-04-03
SI3560937T1 (sl) 2023-04-28
DK3560937T3 (da) 2023-02-13
AU2019203610B2 (en) 2021-02-04
RS64011B1 (sr) 2023-03-31
EP4180438A1 (en) 2023-05-17
EP2970345B1 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
EP2951642A4 (en) OMNISTEREO IMAGING
GB201304149D0 (en) Ultrasound imaging
EP2948047A4 (en) IMAGING BODY STRUCTURES
EP2996149A4 (en) SEMICONDUCTOR IMAGING DEVICE
GB201315248D0 (en) Imaging
HUE046194T2 (hu) 18F-jelölt PSMA-célzott PET képalkotó ágensek
EP2866445A4 (en) IMAGING DEVICE
EP2964658A4 (en) SUBSTITUTED ORGANOFLUOROBORATES AS IMAGING AGENTS
HK1213459A1 (zh) 醫療成像
EP3007435A4 (en) SOLID STATE IMAGING DEVICE
EP3041222A4 (en) IMAGING DEVICE
PL3038468T3 (pl) Środek bakteriobójczy
PL3011321T3 (pl) Obrazowanie rentgenowskie z kodowaną przesłoną
EP2944266A4 (en) ULTRASOUND IMAGING DEVICE
EP3087920A4 (en) IMAGING DEVICE FOR ANIMALS
EP2950517A4 (en) IMAGING DEVICE
GB201319610D0 (en) Image processor
EP2980561A4 (en) IMAGING SYSTEM
GB2530691B (en) Radiation imaging
SG10201801993WA (en) Photoacoustic imaging contrast agent composition
EP2975836A4 (en) IMAGING DEVICE
GB201322068D0 (en) Barrier components for animal stalls
GB201302036D0 (en) Diagnosis
GB201402877D0 (en) Bait Fixing device
EP2975840A4 (en) SEMICONDUCTOR IMAGE FORMING DEVICE